Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012

CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


Age-related macular degeneration before and after the era of anti-VEGF drugs
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye.

St. Joseph's Hospital research reveals standard treatment for ovarian cancer
Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation.

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision.

Half of elderly colorectal cancer patients receiving value-less treatment
A study published online ahead of print in the journal Medical Care shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent.

Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS
Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.

Ranibizumab found effective against diabetic retinopathy
In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab -- a drug most commonly used to treat retinal swelling in people with diabetes -- is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease.

Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer
A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment.

Fears of potentially blinding complication from Avastin eye injections overblown, says Penn study
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.

Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit.
More Bevacizumab Current Events and Bevacizumab News Articles

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg, interferon alfa)...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report

Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report
by Dudley Press (Author)


We describe the case of a man who died of an abdominal aortic aneurysm rupture after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Proceeds from the sale of this book go to support an elderly disabled person.

All About Bevacizumab

All About Bevacizumab
by Aneta Zygulska (Author), Krzysztof Krzemieniecki (Author)


Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. No available published data on the influence of bevacizumab on macrocytosis has been so far. This paper attempts to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Moreover, treatment of solid tumors and non-cancerous diseases is discussed in the second part of this paper.

Introducción a la genética humana, 3ª ed. (Spanish Edition)

Introducción a la genética humana, 3ª ed. (Spanish Edition)
by Editorial El Manual Moderno


Los autores de la primera y segunda edición de esta obra, fuimos los Drs. Salvador Armendares y un servidor. Ya han pasado 18 años desde que apareció la primera y 11 de la segunda, por lo que parecía necesario actualizarla una vez más, en vista de los avances considerables del conocimiento en esta área. Para ello y dado el fallecimiento de Salvador en enero de 2010, me pareció necesario invitar a colaborar a dos distinguidos colegas. La Dra. Patricia Grether González, ex alumna mía, conocedora de los aspectos clínicos de la genética y el Dr. Alejandro Zentella Dehesa, investigador básico en el campo de la biología molecular a quien conozco hace relativamente pocos años pero quien parece tener la capacidad de expresar temas complejos de una manera sencilla, característica...

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)
by Marta Mª Valera Rubio (Author)


Estudio comparativo de eficacia entre el esquema XELOX y el esquema XELOX+Bevacizumab en cáncer colorrectal metastásico en una población de un hospital de tercer nivel.

Handbook of Neuro-Oncology Neuroimaging, Second Edition

Handbook of Neuro-Oncology Neuroimaging, Second Edition
by Herbert B. Newton (Editor)


Remarkable progress in neuro-oncology due to increased utilization of advanced imaging in clinical practice continues to accelerate in recent years. Refinements in magnetic resonance imaging (MRI) and computed tomography (CT) technology, and the addition of newer anatomical, functional, and metabolic imaging methods, such as MRS, fMRI, diffusion MRI, and DTI MRI have allowed brain tumor patients to be diagnosed much earlier and to be followed more carefully during treatment. With treatment approaches and the field of neuro-oncology neuroimaging changing rapidly, this second edition of the Handbook of Neuro-Oncology Neuroimaging is so relevant to those in the field, providing a single-source, comprehensive, reference handbook of the most up-to-date clinical and technical information...

  Cotargeting VEGF and Neuropilins with Bevacizumab and Secreted Wnt Inhibitors in Prostate Cancer
by Xiaolin Zi (Author)




Ending Medical Reversal: Improving Outcomes, Saving Lives

Ending Medical Reversal: Improving Outcomes, Saving Lives
by Vinayak K. Prasad (Author), Adam S. Cifu (Author)


We expect medicine to progress in an orderly fashion, with good medical practices being replaced by better ones. But some tests and therapies are discontinued because they are found to be worse, or at least no better, than what they replaced. Medications like Vioxx and procedures such as vertebroplasty for back pain caused by compression fractures are among the medical "advances" that turned out to be dangerous or useless. What Dr. Vinayak K. Prasad and Dr. Adam S. Cifu call medical reversal happens when doctors start using a medication, procedure, or diagnostic tool without a robust evidence base―and then stop using it when it is found not to help, or even to harm, patients.Drs. Prasad and Cifu narrate fascinating stories from every corner of medicine to explore why medical reversals...

Physicians' Cancer Chemotherapy Drug Manual 2016

Physicians' Cancer Chemotherapy Drug Manual 2016
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)


Completely revised and updated for 2016, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens―both on- and off-label―for the treatment of all the major cancers. SPECIAL FEATURES: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like belinostat, blinatumomab, lenvatinib, nivolumab, olaparib, palbociclib, panobinostat, pembrolizumab, and ramucirumab • A specific chapter focused on profiling antiemetic drugs and antiemetic treatment regimens. • Diagrams...

© 2016 BrightSurf.com